M
Matthew Flitter
Researcher at Avid Radiopharmaceuticals
Publications - 12
Citations - 2219
Matthew Flitter is an academic researcher from Avid Radiopharmaceuticals. The author has contributed to research in topics: Florbetaben & Cognitive decline. The author has an hindex of 8, co-authored 12 publications receiving 1876 citations. Previous affiliations of Matthew Flitter include Eli Lilly and Company & Pierre-and-Marie-Curie University.
Papers
More filters
Journal ArticleDOI
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Christopher M. Clark,Julie A. Schneider,Barry J. Bedell,Thomas G. Beach,Warren B. Bilker,Mark A. Mintun,Michael J. Pontecorvo,Franz Hefti,Alan Carpenter,Matthew Flitter,Michael J. Krautkramer,Hank F. Kung,R. Edward Coleman,P. Murali Doraiswamy,Adam S. Fleisher,Marwan N. Sabbagh,Carl H. Sadowsky,Eric M. Reiman,Simone P. Zehntner,Daniel Skovronsky +19 more
TL;DR: Evidence is provided that a molecular imaging procedure can identify β-amyloid pathology in the brains of individuals during life and for the prediction of progression to dementia.
Journal ArticleDOI
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
Christopher M. Clark,Michael J. Pontecorvo,Thomas G. Beach,Barry J. Bedell,R. Edward Coleman,P. Murali Doraiswamy,Adam S. Fleisher,Eric M. Reiman,Marwan N. Sabbagh,Carl H. Sadowsky,Julie A. Schneider,Anupa Arora,Alan Carpenter,Matthew Flitter,Abhinay D. Joshi,Michael J. Krautkramer,Ming Lu,Mark A. Mintun,Daniel Skovronsky +18 more
TL;DR: The results of this study validate the binary visual reading method approved in the USA for clinical use with flor betapir and suggest that florbetapir could be used to distinguish individuals with no or sparse amyloid plaques from those with moderate to frequent plaques.
Journal ArticleDOI
Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes
Adam S. Fleisher,Michael J. Pontecorvo,Michael D. Devous,Ming Lu,Anupa Arora,Stephen P Truocchio,Patricia Aldea,Matthew Flitter,Tricia Locascio,Marybeth Devine,Andrew Siderowf,Thomas G. Beach,Thomas J. Montine,Geidy E. Serrano,Craig Curtis,Allison Perrin,Stephen Salloway,Misty Daniel,Charles Wellman,Abhinay D. Joshi,David J. Irwin,Val J. Lowe,William W. Seeley,Milos D. Ikonomovic,Joseph C. Masdeu,Ian Kennedy,Thomas S. Harris,Michael Navitsky,Sudeepti Southekal,Mark A. Mintun,A Study Investigators +30 more
TL;DR: The findings suggest that PET imaging with [18F]flortaucipir could be used to identify the density and distribution of AD-type tau pathology and the presence of high levels of AD neuropathological change.
Journal ArticleDOI
Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals
Reisa A. Sperling,Keith A. Johnson,Keith A. Johnson,P. Murali Doraiswamy,Eric M. Reiman,Adam S. Fleisher,Marwan N. Sabbagh,Carl H. Sadowsky,Alan Carpenter,Mat D. Davis,Ming Lu,Matthew Flitter,Abhinay D. Joshi,Christopher M. Clark,Michael Grundman,Mark A. Mintun,Daniel Skovronsky,Michael J. Pontecorvo +17 more
TL;DR: Findings support the hypothesis that higher amyloid burden is associated with lower memory performance among clinically normal older subjects and follow-up is ongoing to determine whether (18)F-AV-45 may also predict subsequent cognitive decline.
Journal ArticleDOI
Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline.
Michael Grundman,Michael J. Pontecorvo,Stephen Salloway,P. M. Doraiswamy,Adam S. Fleisher,Carl H. Sadowsky,Anil K. Nair,Andrew Siderowf,Ming Lu,Anupa Arora,Agbulos A,Matthew Flitter,Michael J. Krautkramer,Sarsour K,Daniel Skovronsky,Mark A. Mintun +15 more
TL;DR: In summary, amyloid imaging results altered physician’s diagnostic thinking, intended testing, and management of patients undergoing evaluation for cognitive decline.